



BOARD OF DIRECTORS

Alok Sonig, Board Chair
Lupin Pharmaceuticals, Inc.

Aaron Mann
3M Health Care Business

Gerald Price
Accord Healthcare Inc.

Harsher Singh
American Regent

Chirag Patel
Amneal Pharmaceuticals, Inc.

Jeff Watson
Apotex Corporation

Jeff Gardner
Argentum Pharmaceuticals

Hunter Murdock
Aurobindo Pharma USA Inc.

Barbara Purcell
Bausch Health

Nikhil Lalwani
Cipla USA, Inc.
(InvaGen Pharmaceuticals, Inc.)

Vanessa Brill
Dr. Reddy's Laboratories Inc.

John Ducker
Fresenius Kabi USA, LLC

Robert Matsuk
Glenmark Pharmaceuticals, Inc., USA

Andrew Callos
Greenstone LLC, a subsidiary of Pfizer

Brian Hoffmann
Hikma Pharmaceuticals

Terry Fullem
Jubilant Cadista Pharmaceuticals, Inc.

Spiro Gavaris
Mallinckrodt, Inc.

Daniel Moore
Mayne Pharma Group, Limited

Marcie McClintic Coates
Mylan, N.V.

Vincent Mancinelli II
Rhodes Pharmaceuticals

Peter Kaemmerer
Sagent Pharmaceuticals, Inc.

Carol Lynch
Sandoz Inc., a Novartis Division

Stephen Manzano
Sun Pharmaceutical Industries, Inc.

Brendan O'Grady
Teva Pharmaceuticals USA

Joe Renner
Zydus Pharmaceuticals USA

The President
The White House
1600 Pennsylvania Avenue
Washington, DC 20500

Chester "Chip" Davis, Jr.
Association for Accessible Medicines
601 New Jersey Avenue NW
Suite 850
Washington, DC 20001

Dear Mr. President:

Under your leadership, prescription drug prices in the United States dropped for the first time in 45 years, as recently reported by the Department of Health and Human Services. Increased patient access to generic medicines and decreases in their prices played a key role in this accomplishment. With 90% of prescriptions filled by generic medicines, meaningful cost savings are being delivered at the pharmacy counter to America's patients every day.

More generic drug applications have been approved by the FDA in recent years as a result of your Administration's emphasis on increasing competition and prioritizing patient access to safe, affordable generic medicines. As a result, 93% of generic drugs are available to patients at a co-pay of \$20 or less.

But your progress in lowering drug prices for Americans is now at risk.

The Lower Health Care Costs Act, under consideration in both the House and Senate, includes a provision (Section 407 – the BLOCKING Act) that would significantly harm the competition that lowers prescription drug prices for America's patients and taxpayers.

The BLOCKING Act would undermine the only incentive generic drug developers have to file their applications with the FDA as early as possible – to bring savings to patients and taxpayers as quickly as possible. This proposal would result in delayed price competition from FDA-approved generic medicines and longer monopolies for expensive brand-name drugs.

A new study by Matrix Global Advisors concludes that the BLOCKING Act will cost the United States health care system \$1.7 billion for each generic drug that is delayed by this provision if it becomes law. But Mr. President, you can block the BLOCKING Act.

Please oppose the BLOCKING Act so that Congress does not destroy your pro-competitive policies that have produced such savings over the last three years. Developers of generic and biosimilar medicines stand ready to assist you to achieve our shared goal of ensuring that all Americans have access to more affordable prescription medicines.

Sincerely,

Chester "Chip" Davis, Jr.
President and Chief Executive Officer
Association for Accessible Medicines